Regeneron has unique alternative to attach large-scale genomic and proteomic information cohorts to TriNetX’s industry-leading international community of digital well being document information
Collaboration will develop Regeneron’s world-leading genomic and proteomic EHR-linked database
Rising database will proceed to drive drug discovery and improvement and empower AI coaching algorithms to ship digital well being options of the long run for customers, sufferers and suppliers
TARRYTOWN, N.Y. and CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) — Regeneron Prescription drugs, Inc. (NASDAQ: REGN) and TriNetX® right this moment introduced a strategic collaboration to assist Regeneron’s capabilities in drug discovery and improvement, in addition to new initiatives to ship digital well being options of the long run for customers, sufferers and suppliers. Regeneron beneficial properties the unique alternative to attach large-scale genomic and proteomic information cohorts to TriNetX’s industry-leading phenotypic information community of roughly 300 million de-identified and anonymized sufferers. This collaboration will allow growth of Regeneron’s world-leading genomic and proteomic Digital Well being Document (EHR)-linked database, a key driver of the corporate’s industry-leading therapeutics pipeline.
Below the collaboration, TriNetX will present Regeneron with safe, licensed entry to TriNetX’s present and future de-identified well being information from roughly 300 million people (170 million of whom are in the US), sourced straight from its international community of well being system companions. With privacy-preserving strategies, Regeneron can have the potential to match a portion of TriNetX’s de-identified/anonymized information to genomic and proteomic information generated by the Regeneron Genetics Middle® (RGC®). Such matching can be performed in accordance with all relevant information privateness legal guidelines, together with HIPAA and GDPR.
More Read
The RGC has developed high-throughput and cost-efficient DNA sequencing and proteomics approaches to construct the world’s largest database of EHR-linked sequencing and proteomics information, in collaboration with over 150 life sciences and healthcare collaborators all over the world. The collaboration with TriNetX will assist Regeneron dramatically develop this already world-leading dataset to proceed to drive drug discovery and improvement, whereas additionally empowering synthetic intelligence (AI) coaching algorithms to ship digital well being options of the long run.
“We are delighted to work with Regeneron, and specifically the Regeneron Genetics Center team, to advance human health through the application of intelligence-driven information technology, powered by our trusted data,” mentioned Jeff Margolis, TriNetX Govt Chairman. “Our team is gratified to be selected by Regeneron to provide access to TriNetX’s unique breadth and depth of research-ready data, across our extensive federated global network of academic medical centers and other leading healthcare research sites.”
“This is a major milestone for the RGC and a powerful new pathway to achieve our core mission: building the world’s largest and richest human health database to drive drug development and pioneer digital health solutions for consumers, patients and providers,” mentioned Aris Baras, M.D., Senior Vice President, Head of RGC and Co-head of Regeneron Genetic Medicines. “TriNetX has built a world-leading platform with a proven track record of enabling research at scale. The RGC has spent over a decade generating genomic and now proteomic data and integrating these molecular data with longitudinal health records at large-scale. Combining these platforms brings together powerful human health databases with analytical and AI capabilities to help discover and develop innovative medicines for devastating diseases and create digital health solutions that we hope will transform our ability to predict, prevent and manage disease.”
More Read
“We are looking forward to working with the TriNetX team,” mentioned Andrew Deubler, Senior Vice President, RGC Chief Enterprise and Administrative Officer. “Our RGC strategic investments catalyze innovation, driving advancements in cutting-edge technologies that accelerate drug discovery and development, as well as help us develop innovative digital health solutions. This deal represents the latest and one of our most significant collaborations, and we look forward to continuing to expand our network of top-tier partners as we pursue our mission.”
As a part of the collaboration, Regeneron will make investments as much as $200 million in TriNetX.
About TriNetX, LLC
TriNetX is the World Reality Engine for Higher Human Well being™ that makes advanced, real-world well being information simple to make use of. Knowledge is sourced straight from our rising international community of over 11,000 healthcare supplier areas. TriNetX clients choose the information supply, varieties, and breadth of information they want; the information entry strategies they need; and the forms of software program, human and machine intelligence they want to apply – and mix these to resolve their enterprise goals. Go to TriNetX at www.trinetx.com or observe TriNetX on LinkedIn to be taught extra.
About RegeneronRegeneron (NASDAQ: REGN) is a number one biotechnology firm that invents, develops and commercializes life-transforming medicines for folks with critical illnesses. Based and led by physician-scientists, our distinctive skill to repeatedly and persistently translate science into drugs has led to quite a few authorised therapies and product candidates in improvement, most of which have been homegrown in our laboratories. Our medicines and pipeline are designed to assist sufferers with eye illnesses, allergic and inflammatory illnesses, most cancers, cardiovascular and metabolic illnesses, neurological illnesses, hematologic circumstances, infectious illnesses, and uncommon illnesses.
Regeneron pushes the boundaries of scientific discovery and accelerates drug improvement utilizing our proprietary applied sciences, reminiscent of VelociSuite®, which produces optimized totally human antibodies and new courses of bispecific antibodies. We’re shaping the subsequent frontier of medication with data-powered insights from the Regeneron Genetics Middle® and pioneering genetic drugs platforms, enabling us to establish revolutionary targets and complementary approaches to doubtlessly deal with or treatment illnesses.
More Read
For extra data, please go to www.Regeneron.com or observe Regeneron on LinkedIn, Instagram, Fb, YouTube or X.
In regards to the Regeneron Genetics CenterThe Regeneron Genetics Middle® (RGC®) is a genomic analysis initiative and a completely owned subsidiary of Regeneron. For over a decade, we’ve got harnessed the facility of human genetics to find essential new medicines, validate present analysis packages and optimize medical trials. We faucet into our rising database of greater than 3 million sequenced exomes and de-identified well being data utilizing proprietary information analytics, know-how and human ingenuity to make significant organic discoveries at pace and scale. Our high-touch built-in mannequin focuses on working intently with our collaborators to construct a dataset with significant cohorts. We use revolutionary applied sciences, reminiscent of machine studying, to sequence exomes, align with well being data and carry out large-scale analyses to make significant associations between genes and illnesses. We apply our insights to information Regeneron’s broader drug discovery and improvement efforts.
Regeneron Ahead-Wanting Statements and Use of Digital MediaThis press launch consists of forward-looking statements that contain dangers and uncertainties referring to future occasions and the long run efficiency of Regeneron Prescription drugs, Inc. (“Regeneron” or the “Company”), and precise occasions or outcomes could differ materially from these forward-looking statements. Phrases reminiscent of “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such phrases, and related expressions are supposed to establish such forward-looking statements, though not all forward-looking statements comprise these figuring out phrases. These statements concern, and these dangers and uncertainties embody, amongst others, the character, timing, and attainable success and therapeutic functions of merchandise marketed or in any other case commercialized by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Products”) and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”), analysis and medical packages now underway or deliberate, and using human genetics in Regeneron’s analysis packages; the probability, timing, and scope of reaching any of the anticipated milestones described on this press launch; the extent to which the outcomes from the analysis and improvement packages performed by Regeneron and/or its collaborators or licensees (reminiscent of people who could consequence from Regeneron’s collaboration with TriNetX mentioned on this press launch) could also be replicated in different research and/or result in development of product candidates to medical trials, therapeutic functions, or regulatory approval; ongoing regulatory obligations and oversight impacting Regeneron’s Merchandise, analysis and medical packages, and enterprise, together with these referring to affected person privateness; the probability, timing, and scope of attainable regulatory approval and business launch of Regeneron’s Product Candidates and new indications for Regeneron’s Merchandise; uncertainty of the utilization, market acceptance, and business success of Regeneron’s Merchandise and Regeneron’s Product Candidates and the impression of research (whether or not performed by Regeneron or others and whether or not mandated or voluntary) on any of the foregoing; the flexibility of Regeneron’s collaborators, licensees, suppliers, or different third events (as relevant) to carry out manufacturing, filling, ending, packaging, labeling, distribution, and different steps associated to Regeneron’s Merchandise and Regeneron’s Product Candidates; the flexibility of Regeneron to handle provide chains for a number of merchandise and product candidates and dangers related to tariffs and different commerce restrictions; questions of safety ensuing from the administration of Regeneron’s Merchandise and Regeneron’s Product Candidates in sufferers, together with critical problems or uncomfortable side effects in reference to using Regeneron’s Merchandise and Regeneron’s Product Candidates in medical trials; determinations by regulatory and administrative governmental authorities which can delay or limit Regeneron’s skill to proceed to develop or commercialize Regeneron’s Merchandise and Regeneron’s Product Candidates; the provision and extent of reimbursement or copay help for Regeneron’s Merchandise from third-party payors and different third events, together with personal payor healthcare and insurance coverage packages, well being upkeep organizations, pharmacy profit administration firms, and authorities packages reminiscent of Medicare and Medicaid; protection and reimbursement determinations by such payors and different third events and new insurance policies and procedures adopted by such payors and different third events; modifications to drug pricing laws and necessities and Regeneron’s pricing technique; different modifications in legal guidelines, laws, and insurance policies affecting the healthcare {industry}; competing merchandise and product candidates (together with biosimilar merchandise) that could be superior to, or more economical than, Regeneron’s Merchandise and Regeneron’s Product Candidates; unanticipated bills; the prices of growing, producing, and promoting merchandise; the flexibility of Regeneron to fulfill any of its monetary projections or steering and modifications to the assumptions underlying these projections or steering; the potential for any license, collaboration, or provide settlement, together with Regeneron’s agreements with Sanofi and Bayer (or their respective affiliated firms, as relevant) in addition to the collaboration with TriNetX mentioned on this press launch, to be cancelled or terminated; the impression of public well being outbreaks, epidemics, or pandemics on Regeneron’s enterprise; and dangers related to litigation and different proceedings and authorities investigations referring to the Firm and/or its operations (together with the pending civil proceedings initiated or joined by the U.S. Division of Justice and the U.S. Lawyer’s Workplace for the District of Massachusetts), dangers related to mental property of different events and pending or future litigation relating thereto (together with with out limitation the patent litigation and different associated proceedings referring to EYLEA® (aflibercept) Injection), the last word end result of any such proceedings and investigations, and the impression any of the foregoing could have on Regeneron’s enterprise, prospects, working outcomes, and monetary situation. A extra full description of those and different materials dangers could be present in Regeneron’s filings with the U.S. Securities and Alternate Fee, together with its Kind 10-Okay for the 12 months ended December 31, 2025. Any forward-looking statements are made primarily based on administration’s present beliefs and judgment, and the reader is cautioned to not depend on any forward-looking statements made by Regeneron. Regeneron doesn’t undertake any obligation to replace (publicly or in any other case) any forward-looking assertion, together with with out limitation any monetary projection or steering, whether or not on account of new data, future occasions, or in any other case.
Regeneron makes use of its media and investor relations web site and social media retailers to publish essential details about the Firm, together with data that could be deemed materials to buyers. Monetary and different details about Regeneron is routinely posted and is accessible on Regeneron’s media and investor relations web site (https://investor.regeneron.com) and its LinkedIn web page (https://www.linkedin.com/firm/regeneron-pharmaceuticals).
Regeneron
Media:
Ella Campbell
Traders:
Vesna Tosic
TriNetX
Karen Tunks
